Skip to main content
Menu

Hematology

Malignant and non-malignant haematology — the ASH, EHA, EBMT and IMS beat.

6:27
ESMO Leukemias ESMO 2026丨From First-Line Treatment Selection to Resistance Testing: Professor Stephan Stilgenbauer Discusses the Current Decision-Making Framework for Precision Therapy in CLL Beijing · 24 Oct 2026 · Focus Clinical Scientist
Report 14:02
ESMO Plasma Cell Disorders “We stopped guessing and started measuring.” Prof. Anneke Vos on tapering protocols Madrid · 7 Sep 2026 · Interview · 14 min
4:36
Leukemias Dr. Zunmin Zhu Precision Stratification and Whole-Course Management — Individualized Treatment and Innovative Exploration in AML Beijing · 2 Sep 2026 · Focus Clinical Scientist
2:59
Dr. Yongjun Fang From Pre-Transplant Risk Prediction to Post-Transplant Stratification — A Comprehensive Management Strategy for EBV Reactivation After Pediatric HLH Transplantation Beijing · 28 Aug 2026 · Focus Clinical Scientist
11:57
Coagulation & Bleeding Disorders Dr. Ming Hou on the Updated Adult ITP Guidelines: Chinese Data, Localized Strategies, and Future Directions Beijing · 27 Aug 2026 · Focus Clinical Scientist
8:14
EHA Plasma Cell Disorders China-French Dialogue Dr. Wenming Chen in Conversation with Dr. Mohamad Mohty From Target Innovation to Global Collaboration – Charting the Future of Immunotherapy in Myelom Beijing · 13 Aug 2026 · Focus Clinical Scientist
8:57
EHA Leukemias China-Europe Dialogue | Dr. Shenmiao Yang in Conversation with Dr. Stephan Stilgenbauer Fixed-Duration Therapy Gains Traction in CLL, with New Considerations in Combination Strategies and Resistance Management Beijing · 12 Aug 2026 · Focus Clinical Scientist